IL109235A - Pharmaceuticals containing a history of oreido for the treatment of diseases caused by the virus virus - Google Patents

Pharmaceuticals containing a history of oreido for the treatment of diseases caused by the virus virus

Info

Publication number: IL109235A
Authority: IL; Israel
Prior art keywords: imino; bis; carbonyl; pyrrole; methyl
Prior art date: 1993-04-16

Application number

IL10923594A

Other languages

English (en)

Hebrew (he)

Other versions

IL109235A0 (en

Inventor

Nicola Mongelli

Giovanni Biasoli

Maria Grandi

Marina Ciomei

Maria Cristina Geroni

Original Assignee

Pharmacia & Upjohn Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-16

Filing date

1994-04-06

Publication date

1998-09-24

1994-04-06 Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa

1994-07-31 Publication of IL109235A0 publication Critical patent/IL109235A0/xx

1998-09-24 Publication of IL109235A publication Critical patent/IL109235A/en

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 15
201000010099 disease Diseases 0.000 title claims description 14
239000008194 pharmaceutical composition Substances 0.000 title claims description 14
238000011282 treatment Methods 0.000 title claims description 14
241000713666 Lentivirus Species 0.000 title claims description 13
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 title description 4
-1 carbonyl imino Chemical group 0.000 claims description 150
150000001875 compounds Chemical class 0.000 claims description 54
150000003839 salts Chemical class 0.000 claims description 39
125000001841 imino group Chemical group [H]N=* 0.000 claims description 11
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 11
241000725303 Human immunodeficiency virus Species 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 10
208000021601 lentivirus infection Diseases 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
HEWDOWUUTBCVJP-UHFFFAOYSA-N naphthalene-1,6-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 HEWDOWUUTBCVJP-UHFFFAOYSA-N 0.000 claims description 9
FKORGLNGEASTQE-UHFFFAOYSA-N naphthalene-1,3-disulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC(S(O)(=O)=O)=C21 FKORGLNGEASTQE-UHFFFAOYSA-N 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 7
INMHJULHWVWVFN-UHFFFAOYSA-N naphthalene-1,3,5-trisulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC(S(O)(=O)=O)=C21 INMHJULHWVWVFN-UHFFFAOYSA-N 0.000 claims description 7
XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims description 7
HYFMZOAPNQAXHU-UHFFFAOYSA-N naphthalene-1,7-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC=C21 HYFMZOAPNQAXHU-UHFFFAOYSA-N 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
239000011734 sodium Substances 0.000 claims description 6
125000000542 sulfonic acid group Chemical group 0.000 claims description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
ZPBSAMLXSQCSOX-UHFFFAOYSA-N naphthalene-1,3,6-trisulfonic acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=CC2=CC(S(=O)(=O)O)=CC=C21 ZPBSAMLXSQCSOX-UHFFFAOYSA-N 0.000 claims description 5
FEWNRIKJXAQRJJ-UHFFFAOYSA-N naphthalene-1,3,7-trisulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC=C21 FEWNRIKJXAQRJJ-UHFFFAOYSA-N 0.000 claims description 5
BBCBMZZXCBYNRL-UHFFFAOYSA-N naphthalene-1,6,7-trisulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=C2C=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC2=C1 BBCBMZZXCBYNRL-UHFFFAOYSA-N 0.000 claims description 5
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims description 5
229910052708 sodium Inorganic materials 0.000 claims description 5
208000015181 infectious disease Diseases 0.000 claims description 4
FMHFHTQXVYDQRT-UHFFFAOYSA-N naphthalene-1,4,6-trisulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC=C21 FMHFHTQXVYDQRT-UHFFFAOYSA-N 0.000 claims description 4
FITZJYAVATZPMJ-UHFFFAOYSA-N naphthalene-2,6-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=CC2=CC(S(=O)(=O)O)=CC=C21 FITZJYAVATZPMJ-UHFFFAOYSA-N 0.000 claims description 4
VILFVXYKHXVYAB-UHFFFAOYSA-N naphthalene-2,7-disulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=CC2=CC(S(=O)(=O)O)=CC=C21 VILFVXYKHXVYAB-UHFFFAOYSA-N 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
230000001575 pathological effect Effects 0.000 claims description 4
208000024891 symptom Diseases 0.000 claims description 4
102100034343 Integrase Human genes 0.000 claims description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 2
239000004599 antimicrobial Substances 0.000 claims description 2
239000002246 antineoplastic agent Substances 0.000 claims description 2
YKFJUBNDHOLBNN-UHFFFAOYSA-N naphthalene-2,3-disulfonic acid Chemical compound C1=CC=C2C=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC2=C1 YKFJUBNDHOLBNN-UHFFFAOYSA-N 0.000 claims description 2
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
208000030507 AIDS Diseases 0.000 description 8
238000000034 method Methods 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
206010001513 AIDS related complex Diseases 0.000 description 4
208000031886 HIV Infections Diseases 0.000 description 4
241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
SLMLLDNYTCBXBW-UHFFFAOYSA-J tetrasodium naphthalene-1,7-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)c1ccc2cccc(c2c1)S([O-])(=O)=O.[O-]S(=O)(=O)c1ccc2cccc(c2c1)S([O-])(=O)=O SLMLLDNYTCBXBW-UHFFFAOYSA-J 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
NMYPVNCHTWFDNI-UHFFFAOYSA-L disodium naphthalene-1-sulfonate Chemical compound [Na+].[Na+].C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1.C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 NMYPVNCHTWFDNI-UHFFFAOYSA-L 0.000 description 3
238000001802 infusion Methods 0.000 description 3
150000007529 inorganic bases Chemical class 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
239000002243 precursor Substances 0.000 description 3
SSPQHAKUUKFFBB-UHFFFAOYSA-J tetrasodium naphthalene-1,3-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].C1(=CC(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1(=CC(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-] SSPQHAKUUKFFBB-UHFFFAOYSA-J 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
101150052863 THY1 gene Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
LEGXVVLDSYRFIN-UHFFFAOYSA-J [K+].[K+].[K+].[K+].C1(=CC(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1(=CC(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-] Chemical compound [K+].[K+].[K+].[K+].C1(=CC(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1(=CC(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-] LEGXVVLDSYRFIN-UHFFFAOYSA-J 0.000 description 2
NRWWXYQCNZUYML-UHFFFAOYSA-J [Na+].[Na+].[Na+].[Na+].C1=C(C=CC2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C=CC2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(C=CC2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C=CC2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-] NRWWXYQCNZUYML-UHFFFAOYSA-J 0.000 description 2
LDVYOHCBMQRNFV-UHFFFAOYSA-J [Na+].[Na+].[Na+].[Na+].C1=C(C=CC=2C(=CC=CC12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C=CC=2C(=CC=CC12)S(=O)(=O)[O-])S(=O)(=O)[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(C=CC=2C(=CC=CC12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C=CC=2C(=CC=CC12)S(=O)(=O)[O-])S(=O)(=O)[O-] LDVYOHCBMQRNFV-UHFFFAOYSA-J 0.000 description 2
GMTVEOTXIIJCEP-UHFFFAOYSA-H [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1(=CC=C(C2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].C1(=CC=C(C2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1(=CC=C(C2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].C1(=CC=C(C2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-] GMTVEOTXIIJCEP-UHFFFAOYSA-H 0.000 description 2
FCLVESYQTSOUMH-UHFFFAOYSA-J [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)c1cccc2c(cccc12)S([O-])(=O)=O.[O-]S(=O)(=O)c1cccc2c(cccc12)S([O-])(=O)=O Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)c1cccc2c(cccc12)S([O-])(=O)=O.[O-]S(=O)(=O)c1cccc2c(cccc12)S([O-])(=O)=O FCLVESYQTSOUMH-UHFFFAOYSA-J 0.000 description 2
239000002253 acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
229940124411 anti-hiv antiviral agent Drugs 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
NFWQRTJHAGRZDD-UHFFFAOYSA-L disodium naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)c1ccc2ccccc2c1.[O-]S(=O)(=O)c1ccc2ccccc2c1 NFWQRTJHAGRZDD-UHFFFAOYSA-L 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
159000000001 potassium salts Chemical class 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
HYSBOMDYYIJYKS-UHFFFAOYSA-J tetrasodium naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)c1ccc2ccc(cc2c1)S([O-])(=O)=O.[O-]S(=O)(=O)c1ccc2ccc(cc2c1)S([O-])(=O)=O HYSBOMDYYIJYKS-UHFFFAOYSA-J 0.000 description 2
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
SAIKULLUBZKPDA-UHFFFAOYSA-N Bis(2-ethylhexyl) amine Chemical compound CCCCC(CC)CNCC(CC)CCCC SAIKULLUBZKPDA-UHFFFAOYSA-N 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
101150046236 CNR1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
108010042309 Netropsin Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
206010054979 Secondary immunodeficiency Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
LQKHDTQCYWMWBF-UHFFFAOYSA-J [Na+].[Na+].[Na+].[Na+].C1=C(C(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(C(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-] LQKHDTQCYWMWBF-UHFFFAOYSA-J 0.000 description 1
DQHFTMJCTGBLJG-UHFFFAOYSA-H [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=C(C(=CC=2C(=CC=CC12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C(=CC=2C(=CC=CC12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=C(C(=CC=2C(=CC=CC12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C(=CC=2C(=CC=CC12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-] DQHFTMJCTGBLJG-UHFFFAOYSA-H 0.000 description 1
UQLPMUATSFTEFH-UHFFFAOYSA-H [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=C(C=C(C2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C=C(C2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=C(C=C(C2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].C1=C(C=C(C2=CC(=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-] UQLPMUATSFTEFH-UHFFFAOYSA-H 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
229940121369 angiogenesis inhibitor Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
SKDRUFXXSNZGKK-UHFFFAOYSA-H hexasodium naphthalene-1,3,5-trisulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)c1cc(c2cccc(c2c1)S([O-])(=O)=O)S([O-])(=O)=O.[O-]S(=O)(=O)c1cc(c2cccc(c2c1)S([O-])(=O)=O)S([O-])(=O)=O SKDRUFXXSNZGKK-UHFFFAOYSA-H 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960004393 lidocaine hydrochloride Drugs 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000012514 monoclonal antibody product Substances 0.000 description 1
YPLIFKZBNCNJJN-UHFFFAOYSA-N n,n-bis(ethylamino)ethanamine Chemical compound CCNN(CC)NCC YPLIFKZBNCNJJN-UHFFFAOYSA-N 0.000 description 1
UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 1
229910052754 neon Inorganic materials 0.000 description 1
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
208000015015 neurological dysfunction Diseases 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
150000003233 pyrroles Chemical class 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
108010042747 stallimycin Proteins 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL10923594A 1993-04-16 1994-04-06 Pharmaceuticals containing a history of oreido for the treatment of diseases caused by the virus virus IL109235A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB939307948A GB9307948D0 (en)	1993-04-16	1993-04-16	Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease

Publications (2)

Publication Number	Publication Date
IL109235A0 IL109235A0 (en)	1994-07-31
IL109235A true IL109235A (en)	1998-09-24

Family

ID=10733998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10923594A IL109235A (en)	1993-04-16	1994-04-06	Pharmaceuticals containing a history of oreido for the treatment of diseases caused by the virus virus

Country Status (15)

Country	Link
EP (1)	EP0646004A1 (ru)
JP (1)	JPH07508044A (ru)
KR (1)	KR950701812A (ru)
AU (1)	AU670194B2 (ru)
CA (1)	CA2137148A1 (ru)
CZ (1)	CZ282988B6 (ru)
GB (1)	GB9307948D0 (ru)
HU (1)	HU216834B (ru)
IL (1)	IL109235A (ru)
NO (1)	NO307126B1 (ru)
PL (1)	PL306798A1 (ru)
RU (1)	RU2142798C1 (ru)
TW (1)	TW308593B (ru)
UA (1)	UA42693C2 (ru)
WO (1)	WO1994023718A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9504065D0 (en) *	1995-03-01	1995-04-19	Pharmacia Spa	Poly-pyrrolecarboxamidonaphthalenic acid derivatives
GB9602721D0 (en) *	1996-02-09	1996-04-10	Pharmacia Spa	Biologically active ureido derivatives useful in the treatment of multiple sclerosis
GB2310207A (en) *	1996-02-15	1997-08-20	Pharmacia Spa	Antiviral ureido derivatives of substituted heterocyclic compounds
GB9713733D0 (en) *	1997-06-27	1997-09-03	Pharmacia & Upjohn Spa	Poly-branched polycarboxamido compounds
EP3381897A1 (en)	2017-03-27	2018-10-03	Leadiant Biosciences SA	Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9000644D0 (en) *	1990-01-11	1990-03-14	Erba Carlo Spa	New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
AU1224392A (en) *	1991-02-06	1992-09-07	Synphar Laboratories, Inc.	Oligopeptide antiretroviral agents
IT1247878B (it) *	1991-02-15	1995-01-05	Menarini Farma Ind	Derivati poli-4-aminopirrol-2-carbossiamidici,processi di preparazione e composizioni farmaceutiche che li contengono

1993
- 1993-04-16 GB GB939307948A patent/GB9307948D0/en active Pending
1994
- 1994-03-29 PL PL94306798A patent/PL306798A1/xx unknown
- 1994-03-29 CA CA002137148A patent/CA2137148A1/en not_active Abandoned
- 1994-03-29 RU RU94046312A patent/RU2142798C1/ru active
- 1994-03-29 CZ CZ95107A patent/CZ282988B6/cs unknown
- 1994-03-29 AU AU65371/94A patent/AU670194B2/en not_active Ceased
- 1994-03-29 JP JP6522676A patent/JPH07508044A/ja active Pending
- 1994-03-29 WO PCT/EP1994/000984 patent/WO1994023718A1/en not_active Ceased
- 1994-03-29 UA UA94129236A patent/UA42693C2/ru unknown
- 1994-03-29 HU HU9500120A patent/HU216834B/hu not_active IP Right Cessation
- 1994-03-29 EP EP94913075A patent/EP0646004A1/en not_active Withdrawn
- 1994-04-06 IL IL10923594A patent/IL109235A/en not_active IP Right Cessation
- 1994-04-12 TW TW083103216A patent/TW308593B/zh active
- 1994-12-12 NO NO944809A patent/NO307126B1/no not_active IP Right Cessation
- 1994-12-15 KR KR1019940704567A patent/KR950701812A/ko not_active Ceased

Also Published As

Publication number	Publication date
AU6537194A (en)	1994-11-08
NO307126B1 (no)	2000-02-14
JPH07508044A (ja)	1995-09-07
NO944809L (no)	1994-12-12
HU216834B (hu)	1999-09-28
RU2142798C1 (ru)	1999-12-20
CZ10795A3 (en)	1995-09-13
CZ282988B6 (cs)	1997-12-17
RU94046312A (ru)	1996-10-20
PL306798A1 (en)	1995-04-18
HUT71838A (en)	1996-02-28
EP0646004A1 (en)	1995-04-05
CA2137148A1 (en)	1994-10-27
HU9500120D0 (en)	1995-03-28
WO1994023718A1 (en)	1994-10-27
TW308593B (ru)	1997-06-21
GB9307948D0 (en)	1993-06-02
IL109235A0 (en)	1994-07-31
KR950701812A (ko)	1995-05-17
UA42693C2 (ru)	2001-11-15
NO944809D0 (no)	1994-12-12
AU670194B2 (en)	1996-07-04

Publication	Publication Date	Title
EP0462258B1 (en)	1995-12-20	Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
RU2136692C1 (ru)	1999-09-10	Уреидопроизводные нафталинфосфоновых кислот или их фармацевтически приемлемые соли и фармацевтическая композиция на их основе
HK1006455B (en)	1999-02-26	Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
US5534539A (en)	1996-07-09	Biologically active ureido derivatives useful as anit-metastic agenst
MXPA97001949A (en)	1997-06-01	Derivatives of distamycine substituted with bis- (2-haloethyl) aminophenylene as anatomy agents yantivira
EA000033B1 (ru)	1998-02-26	Бис-(2-галоидэтил)аминофенилзамещенные производные дистамицина и их применение в качестве противоопухолевого и противовирусного средства
IL109235A (en)	1998-09-24	Pharmaceuticals containing a history of oreido for the treatment of diseases caused by the virus virus
EP0583161B1 (en)	1999-03-31	4-Aminopyrrole-2-carboxamide derivatives as antiviral agents
WO1999000364A1 (en)	1999-01-07	Poly-branched polycarboxamido compounds
WO1999000363A1 (en)	1999-01-07	Substituted triazine compounds and their use in medicine

Legal Events

Date	Code	Title
1999-01-26	FF	Patent granted
1999-07-14	KB	Patent renewed
2001-06-14	RH	Patent void
2005-07-25	MM9K	Patent not in force due to non-payment of renewal fees